ITCN20090008A1 - Composizione di acido butirrico miscelato con probiotici e prebiotici - Google Patents

Composizione di acido butirrico miscelato con probiotici e prebiotici Download PDF

Info

Publication number
ITCN20090008A1
ITCN20090008A1 IT000008A ITCN20090008A ITCN20090008A1 IT CN20090008 A1 ITCN20090008 A1 IT CN20090008A1 IT 000008 A IT000008 A IT 000008A IT CN20090008 A ITCN20090008 A IT CN20090008A IT CN20090008 A1 ITCN20090008 A1 IT CN20090008A1
Authority
IT
Italy
Prior art keywords
association
ability
butyric acid
intestine
prebiotics
Prior art date
Application number
IT000008A
Other languages
English (en)
Inventor
Daniele Scatolero
Original Assignee
Alpiflor S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITCN20090008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alpiflor S R L filed Critical Alpiflor S R L
Priority to ITCN2009A000008A priority Critical patent/IT1395328B1/it
Priority to ES10171504T priority patent/ES2411687T3/es
Priority to EP10171504A priority patent/EP2289505B1/en
Priority to PT101715043T priority patent/PT2289505E/pt
Publication of ITCN20090008A1 publication Critical patent/ITCN20090008A1/it
Application granted granted Critical
Publication of IT1395328B1 publication Critical patent/IT1395328B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Description

TITOLO COMPOSIZIONE Dì ACIDO BUTIRRICO MISCELATO CON PROBIOTICI E PREBIOTICI
Descrizione :
La presente invenzione si pone nel campo delia tecnica dì produzione dei prodotti alimentari e/o salutistici Attualmente non ci sono ancora sul mercato associazioni di questi tipi di ingredienti (Prebiotico, Probiotico, Acido butirrico e/o suo sale organico e/o inorganico). Sul mercato esistono attualmente in commercio prodotti alimentari salutistici che presentano tali ingredienti solo da soli o in associazioni di Acido butirrico e priebiotico, ma la vera novità à ̈ T'associazione dell'acido butirrico col simbiotico ( miscela di prebiotico e probiotico) che à ̈ la più efficace perché completa dal punto d vista nutritivo a svolgere un’azione salutistica e nutritiva a livello deli’ intestino in generale e del grosso intestino in particolare .
Nella presente invenzione infatti si à ̈ provveduto, attraverso molteplici prove di messa a punto, a riunire in una compressa a rilascio modificato un prebiotico costituito da una fibra alimentare e un probiotico costituito da fermenti lattici vivi e l'acido butirrico o un suo sale e a fare si che l’associazione dei componenti potesse attraversare la barriera gastrica e giungere all’intestino in loto dove poter svolgere la sua azione salutistica.
Composizione tipo :
Cellulosa microcristallina 0,3118980 Dosaggio ingredienti attivi Calcio butirrato 0,3070000 250mg di Ac butirrico Prebiotico 0,1000000 100 mg
Fermento lattico 0,01100 1,02 MLD
Magnesio sterrato 0,0100000
Gomma lacca 0,0100000
PVP 30 0,0050000
Acido citrico 0,0050000
HPMC alta densità 0,1890000
Colorante 0,0000020
Amido modificato 0,0150000
Talco, titanio biossido 0,0150000
In grassetto sono evidenziati gli ingredienti della associazione con indicati i dosaggi tipici della associazione, questi dosaggi possono comunque essere variati sia in aumento che in diminuzione in percentuali variabili da 0 a 300 %. Il problema tecnico à ̈ di far passare la barriera gastrica a tutti e tre gli ingredienti in modo da arrivare nel intestino e nel colon in particolare integri e attivi.
Descrizione di una produzione tipica con soluzione del problema tecnico :
Oli ingredienti previsti dalla soprastante tabella vengono pesati separatamente
1. In un miscelatore per polveri vengono miscelati i seguenti ingredienti precedentemente pesati { Calcio bulinato, Prebiotico, Fermento lattico, PVP30,HPMC alta densità, Cellulosa microcristallina) per almeno 15 minuti
2. Alla miscela così fatta viene aggiunto il magnesio stearato e si continua la miscelazione per altri 5 minuti circa.
3. Si porta un campione della miscela cosi fatta al controllo qualità per le verifiche previste dalla farmacopea per le miscela di poveri { granulometria, omogeneità della miscela, peso specifico apparente, umidità)
4. Utilizzando una comprimitrice opportuna si allestiscono le compresse che andranno a costituire il nucleo del prodotto finito (per questa ricetta tipo il nucleo à ̈ di 935 mg).
5. I nuclei vengono raccolti in appositi contenitori e un campione viene portato al controllo qualità per le verifiche previste dalla farmacopea per le compresse (uniformità di massa [± 5%], carico di rottura [98 Newton ± 3%], umidità [< 8 %], dimensioni [spessore max 7 mm lunghezza 19 mm larghezza 10 mm], friabilità perdita [max I %}, disgregazione [non meno di 9 h a ph > 6.5]) in [] i valori di riferimento
6. Si attende liberazione semilavorato dal controllo qualità
7. SÌ prepara la miscela di filmatura enterica si pesa la gomma lacca e si scioglie in etanolo assoluto, quindi sì spruzza sulle compresse
8. Si spruzza la gomma lacca fino a che il peso medio delle compresse à ̈ aumentato di quanto previsto dalla ricetta ( in questo caso peso medio nucleo 10 mg )
9. Si prepara la miscela di filmatura finale pesando l’Amido modificato, il titanio biossido, il talco, il colorante e l'acido citrico e sciogliendo il tutto in acqua
10. Si spruzza sulla compressa rivestita fino al peso finale.
11. Si porta al controllo qualità per verifiche finali ( Uniformità di peso [960 mg ± 3 %],
Disgregazione [> 10 h], conta microbiologica totale [>100 ufc/g, lieviti e muffe >10fc/g, salmonelle assenti in 10 g, patogeni assenti])
12. Confezionamento finale in blister o pilloliera

Claims (1)

  1. TITOLO COMPOSIZIONE DI ACIDO BUTIRRICO MISCELATO CON PROBIOTICI E PREBIOTICI RIVENDICAZIONI La presente invenzione RIVENDICA : J ) nel campo della produzione dei prodotti alimentari e/o salutistici P'associazione di questi tipi di ingredienti in qualunque dosaggio Prebiotico, Probiotico, Acido butirrico e/o suo sale organico e/o inorganico, 2) Γ associazione dell’acido butirrico col simbiotico ( miscela di prebiotico e probiotico) che à ̈ la più efficace perché completa dal punto di vista nutritivo a svolgere un’azione salutistica e nutritiva a livello dell ’intestino in generale e del grosso intestino in particolare . 3) La capacità dell’associazione di migliorare l’assorbimento dei nutrienti 4) La capacità dell'associazione di promuovere un corretto funzionamento del sistema immunitario 5) La capacità della associazione di mantenere Γ integrità funzionale e strutturale della mucosa intestinale 6} La capacità della associazione di promuovere la crescita selettiva dei fermenti saprofiti nell’ intestino.
ITCN2009A000008A 2009-08-26 2009-08-26 Composizione di acido butirrico miscelato con probiotici e prebiotici IT1395328B1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITCN2009A000008A IT1395328B1 (it) 2009-08-26 2009-08-26 Composizione di acido butirrico miscelato con probiotici e prebiotici
ES10171504T ES2411687T3 (es) 2009-08-26 2010-07-30 Composición nutricional y complemento alimentario que contiene dicha composición nutricional
EP10171504A EP2289505B1 (en) 2009-08-26 2010-07-30 Nutritional composition and food supplement containing such a nutritional composition.
PT101715043T PT2289505E (pt) 2009-08-26 2010-07-30 Composição nutricional e suplemento alimentar contendo essa composição nutricional

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITCN2009A000008A IT1395328B1 (it) 2009-08-26 2009-08-26 Composizione di acido butirrico miscelato con probiotici e prebiotici

Publications (2)

Publication Number Publication Date
ITCN20090008A1 true ITCN20090008A1 (it) 2011-02-27
IT1395328B1 IT1395328B1 (it) 2012-09-14

Family

ID=41683333

Family Applications (1)

Application Number Title Priority Date Filing Date
ITCN2009A000008A IT1395328B1 (it) 2009-08-26 2009-08-26 Composizione di acido butirrico miscelato con probiotici e prebiotici

Country Status (4)

Country Link
EP (1) EP2289505B1 (it)
ES (1) ES2411687T3 (it)
IT (1) IT1395328B1 (it)
PT (1) PT2289505E (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027042B1 (ru) 2011-03-15 2017-06-30 Компани Жервэ Данон Пластиковая фланцевая емкость и упаковка для пищевых продуктов, содержащая такие емкости
NL2009744C2 (en) * 2012-11-02 2014-05-06 Palital Gmbh & Co Kg New method to compose and process an animal feed additive with butyrate.
US10206884B2 (en) 2013-12-20 2019-02-19 Fresenius Kabi Deutschland Gmbh Microcapsules with polymeric coating comprising a lipid and an active agent
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
AU2016351455B2 (en) * 2015-11-09 2020-08-20 Mjn U.S. Holdings Llc Nutritional compositions comprising Lactobacillus rhamnosus GG, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
ITUB20159138A1 (it) * 2015-12-22 2017-06-22 Euro Pharma Srl Formulazioni terapeutiche integrative per la somministrazione separata, sequenziale o simultanea di acido butirrico, G.S.E probiotici e prebiotici.
EP3426269A4 (en) 2016-03-11 2019-10-16 Evolve Biosystems Inc. FOOD COMPOSITIONS FOR DEHUMIDIFICATION
PL236296B1 (pl) * 2017-08-25 2020-12-28 Przed Produkcji Farmaceutycznej Hasco Lek Spolka Akcyjna Tabletka zawierająca maślan sodu i sposób jej wytwarzania
IT201800005908A1 (it) * 2018-05-31 2019-12-01 Compressa gastroresistente rivestita con film per il rilascio protratto di acido butirrico
IT202200013138A1 (it) 2022-06-22 2023-12-22 Cerbios Pharma Sa Probiotico per l’uso nel trattamento di alterazioni infiammatorie della mucosa intestinale, in particolare obesità
BE1031379B1 (nl) * 2023-08-28 2024-09-18 Hipeva Synergistische samenstelling omvattende boterzuur en agave-fructaan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026316A1 (en) * 2002-09-17 2004-04-01 Danisco A/S Novel use of carbohydrates and compositions
DE10244359A1 (de) * 2002-09-24 2004-04-08 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Futtermittelzusatz enthaltend mindestens eine Säure und/oder deren Salze, mindestens eine resistente Stärke sowie mindestens ein Polyphenol
JP2007131541A (ja) * 2005-11-08 2007-05-31 Kao Corp 成長ホルモン分泌促進剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426099B1 (en) 1997-12-03 2002-07-30 Renew Life, Inc. Herbal formulation for rebuilding intestinal bacteria
AU5124600A (en) 1999-04-26 2000-11-10 Imperial Sensus, L.L.C. Granular delivery system
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
GB2466041A (en) 2008-12-09 2010-06-16 Sanluc Internat Nv Coated granules comprising butyrate salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026316A1 (en) * 2002-09-17 2004-04-01 Danisco A/S Novel use of carbohydrates and compositions
DE10244359A1 (de) * 2002-09-24 2004-04-08 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Futtermittelzusatz enthaltend mindestens eine Säure und/oder deren Salze, mindestens eine resistente Stärke sowie mindestens ein Polyphenol
JP2007131541A (ja) * 2005-11-08 2007-05-31 Kao Corp 成長ホルモン分泌促進剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCESCHI FRANCESCO ET AL: "Role of probiotics in patients with Helicobacter pylori infection", HELICOBACTER, vol. 12, no. Suppl. 2, November 2007 (2007-11-01), pages 59 - 63, XP002571863, ISSN: 1083-4389 *
NILSSON ULF ET AL: "Bifidobacterium lactis Bb-12 and Lactobacillus salivarius UCC500 modify carboxylic acid formation in the hindgut of rats given pectin, inulin, and lactitol", JOURNAL OF NUTRITION, vol. 136, no. 8, August 2006 (2006-08-01), pages 2175 - 2180, XP008119610, ISSN: 0022-3166 *
STROWSKI M Z ET AL: "Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases", GUT 2009 BMJ PUBLISHING GROUP GBR, vol. 58, no. 8, August 2009 (2009-08-01), pages 1044 - 1045, XP008119617 *
WILLIAMS L ET AL: "Dietary fiber and other alternative therapies and irritable bowel syndrome", TOPICS IN CLINICAL NUTRITION 2009 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 24, no. 3, July 2009 (2009-07-01), pages 262 - 271, XP002571864, ISSN: 0883-5691 *

Also Published As

Publication number Publication date
EP2289505A1 (en) 2011-03-02
ES2411687T3 (es) 2013-07-08
EP2289505B1 (en) 2013-03-06
IT1395328B1 (it) 2012-09-14
PT2289505E (pt) 2013-06-12

Similar Documents

Publication Publication Date Title
ITCN20090008A1 (it) Composizione di acido butirrico miscelato con probiotici e prebiotici
CN104288120B (zh) 肠溶植物纤维素硬空心胶囊及其制备方法
CN103301086B (zh) 一种植物纤维素硬空心胶囊的制备方法
AU2014291777B2 (en) A composition having a prebiotic effect
WO2013171697A1 (en) Oral composition comprising a low- availability active ingredient, for use as a medicament or a dietary/supplement/nutraceutical
MX2012006851A (es) Granulos para preparaciones farmceuticas, metodos y aparatos para su produccion.
CA3161418C (en) Multi-strain probiotic composition and its use
Rashed et al. Manipulation of gut microbiota as a key target for crohn's disease
CN102631331A (zh) 奥氮平口腔崩解片制剂及其制备方法
CA2806823A1 (en) Use of a mixture of probiotic bacteria in a mixture with short - chain fatty acids
Sharada et al. Sustained release matrix tablets of indomethacin using hibiscus rosa-sinensis as release retardant
ITMI20110934A1 (it) Tannato di gelatina e sue associazioni per uso nel trattamento di malattie infiammatorie gastrointestinali
Ratnaparkhi Formulation and development of floating drug delivery of Itopride Hcl
CN104906067A (zh) 一种稳定的叶酸包合物的亚铁组合物及其制备方法与制剂
CN103919761B (zh) 一种苯丙氨酸鳌合钙粉及加工方法
Iswandana et al. Formulation of various polysaccharides-based multicoated tablets containing dexamethasone and probiotics for inflammatory bowel disease
Sousa et al. MAFLD under the lens: the role of gut microbiota
CN104666264B (zh) 一种盐酸氨基葡萄糖咀嚼片及其制备方法
Ghosh et al. Probiotic-assisted colon-specific delivery of diclofenac sodium from guar gum matrix tablets: In vitro evaluation
Jackson et al. Ternary blends of some hydrophilic and hydrophobic polymers in colon targeted delivery of diethylcarbamazine
Prajapati et al. Sustained release itopride hydrochloride matrix tablet
Kotadiya et al. In vitro In vivo evaluation of Okragum: guargum compression coated Diclofenac sodium tablets for colonic delivery: a factorial approach
US20230124503A1 (en) Ginsenoside compositions
Gupta et al. Formulation and Evaluation of Orodispersible Tablets of Salbutamol Sulphate
IT202100011798A1 (it) Processo per aumentare la bioaccessibilità intestinale dei polifenoli in un liofilizzato di una matrice vegetale ad alto contenuto di polifenoli